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ABSTRACT                                                                                                                                            
Maternal risk factors in young Egyptian mothers of 
Down syndrome
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Introduction: We investigated the possible maternal risk factors that may 
increase the incidence of Down syndrome (DS) in young Egyptian moth-
ers (younger than 35 years) especially methylene tetrahydrofolate reductase 
(MTHFR) enzyme C677T polymorphism.    
Subjects and Methods: The study included 200 mothers of karyotypically 
ascertained non-disjunction DS attending Genetics clinic, Children’s hospital, 
Ain Shams University (100 mothers were < 35 years and 100 mothers ≥ 35 
years). 50 mothers of none-DS children served as a control group. 
For all cases, history was taken laying stress on: Parental ages at conception, 
maternal grandparent’s ages at conception of mother, DS birth order, history of 
oral contraceptive use 6 months before conception, genital infection, vitamin 
supplementation and smoking or exposure to irradiation. 
Results: MTHFR C677T mutational analysis was done to twenty DS mothers 
with ages ≤ 35 years revealed that 35% of young mothers had C677T muta-
tion (10% had homozygous mutation and 25% had heterozygous mutation). 
MTHFR C677T polymorphism was found to be a possible maternal genetic 
risk factor for DS although statistically non-significant. 
Other maternal risk factors included the use of oral contraceptive pills (OCP) 
6 months before pregnancy which was significantly higher only in DS 
mothers ≥ 35 years. on the other hand, parental consanguinity, maternal grand-
parents’ ages, the presence of genital infection and birth order did not show a 
significant difference between young and old mothers of DS. 
Conclusion: MTHFR C677T could not be considered as a maternal risk factor 
in young Egyptian mothers of DS. The risk effect may depend on gene-envi-
ronment interaction between the genotype and dietary intake in particular folic 
acid consumption which should be further studied on a larger scale population 
including other MTHFR polymorphisms and environmental factors. Other risk 
factors may include the use of OCP in older mothers. Parents consanguinity, 
paternal age and maternal grandparents’ ages were not found to be risk factors 
in DS in this study.








INTRODUCTION                                          
Down syndrome, or trisomy 21, is a 
complex genetic disease resulting from 
the presence of 3 copies of chromosome 
21. The origin of the extra chromosome 
is maternal in 95% of cases and is due 
to failure of normal chromosomal seg-
regation during meiosis. Many risk fac-
tors are suggested to cause DS. The only 
well established risk factor is advanced 
maternal age and so age –specific rates 
have been documented1. Other factors 
include higher socioeconomic status, 
which is due in part to maternal age2, 
advanced paternal age (>49 years)3 and 
birth order.4,5
In 1999, Jill James and colleagues re-
ported that a particular variant (poly-
morphism) of MTHFR might be a 
maternal risk factor for having a child 
with DS and that a significant increase 
in plasma homocysteine levels exists 
in mothers of children with DS. This 
polymorphism is known to decrease the 
activity of MTHFR6. Since then, stud-
ies have been carried out on popula-
tions from different countries including 
Egypt.7
Because most Egyptian children with 
Down syndrome are born to mothers 
less than 35 years of age8, we aimed in 
this study to investigate possible mater-
nal risk factors that may increase the in-
cidence of DS in this Group especially 
MTHFR C677T polymorphism.  
SUBJECTS                                                         
The study included 200 mothers of 
karyotypically ascertained non-disjunc-
tion DS children attending Genetics 
clinic, Children’s hospital, Ain Shams 
University and another 50 mothers of 
non DS children who served as con-
trols. They were classified into: 
Group I: Included 100 young mothers 
of DS (age < 35 years at time of con-
ception).
Group II: Included 100 older mothers 
of DS (age ≥ 35 years at time of concep-
tion).
Group III: Included 25 young mothers 
of normal children (age < 35 years).
Group IV: Included 25 older mothers 
of normal children (age ≥  35 years).
METHODS                                                       
For all cases the following was done:
Full history taking laying stress on: 
parental ages at conception, mater-
nal grandparent’s ages at conception 
of mother, DS birth order, history of 
oral contraceptive use 6 months before 
conception, history of genital infection 
(itching, secretions etc), history of vi-
tamin supplementation before or during 
pregnancy and history of smoking or 
exposure to irradiation.
Twenty mothers from Group I were 
subjected to MTHFR C677T mutation-
al analysis:
A- DNA extraction:
Genomic DNA was extracted us-
ing QIAampl DNA extraction kit 
(Cat≠51104).
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B- Polymerase chain reaction (PCR):
Polymerase chain reaction (PCR) was 
performed according to the method de-
scribed by Frosst et al.9.
1μL of genomic DNA was amplified 
in a 50μL reaction volume containing 
50 mM KCL, 10mM trisHCL pH=8.3, 
1.5 mM MCL2, 20mM dNTPs, 0.5μM 
primers and one unit of Taq DNA poly-
merse enzyme.
PCR consisted of initial denaturation at 
94°C for 150 seconds followed by 35 
cycles at 94°C for 30 seconds, 57°C for 
60 seconds and 72°C for 120 seconds 
and a final elongation step at 72°C for 
3 minutes.
PCR product of 198bp was analyzed on 
3% agarose gel electrophoresis.
C- Enzyme digestion:
Twenty microliter of PCR product was 
mixed with 5 units of Hinf1 (promega, 
Madison) enzyme at 37°C overnight 
incubation. The susbstitution created a 
Hinf1 recognition sequence that is di-
gested into 175-bp and 23-bp.
RESULTS                                                          
Parental and maternal grandparents’ 
ages of both patients and controls are 
shown in (Table 1). Mean paternal age 
was significantly higher in Group II 
while mean maternal grandfathers and 
grandmothers’ age did not show sig-
nificance difference between the two 
Groups, (Table 2). When advanced pa-
ternal age was considered ≥ 49 years10, 
47% of DS fathers in Group I and only 
3% of Group II had advanced age and 
this was highly significant (P value < 
0.001) and when advanced maternal 
grandmothers’ age was considered ≥ 
35 years, 23% of grandmothers had 
advanced age in Group II compared to 
only 7% of Group I which was also sta-
tistically significant (P value < 0.001).
Table 1: Mean and slandered deviation of parents ages and maternal grandparents’ ages of 




Mean ± SD P value
Maternal ages 33.25 ±7.69 31.62 ±8.76 0.19
Paternal ages 39.22 ±9.78 39.92 ±8.86 0.65
Maternal  grandmothers' ages 26.51 ±6.49 27.44 ±6.34 0.36
Maternal grandfather's ages 26.35 ±6.64 27.1 ±6.7 0.48





(mean ± SD) P value
Paternal ages 32.6± 7.53 45.84± 6.87 < 0.001
M. grandmothers' ages 25.99 ± 5.56 27.02 ± 7.29 0.845




Parental consanguinity was present 
in 22% of patients compared to 28% 
in controls with no significant differ-
ence between young (Group I) and old 
(Group II) mothers. OCP were received 
by 37% of DS mothers which is signifi-
cantly higher in old mothers of Group 
II compared to Group I. None specific 
genital infection manifested itching 
or abnormal secretion was present in 
34.5% of DS mothers with no signifi-
cant difference between Group I and II. 
None of the DS mothers received vita-
min supplementation before or during 
pregnancy, (Table 3).
Table 3: Comparison between Group I and II as regards consanguinity, use of oral contracep-






ratio CI P value
 Consanguinity (21) 21 (23)  23 1.12 2.19 0.58- 0.43
Use of oral contraceptives (25) 25 (49) 49 2.88 1.58-5.25 0.001 >
Genital infections (37) 37 (32) 32 0.8 0.45-1.44 0.28
Vitamin supplement 0 0 - - -
None of the DS mothers took vitamin 
supplement before or during pregnancy. 
37 % of DS mothers took oral contra-
ceptive pills in the last 6 moths before 
pregnancy while 34.5% had genital in-
fection. Use of oral contraceptive pills 
6 months before pregnancy was signifi-
cantly higher in Group II while parents’ 
consanguinity, the presence of genital 
infection and birth order did not sig-
nificantly differ between Group I and 
II, (Table 3). Most of DS children were 
the first or second in order of birth and 
did not show significance difference be-
tween young and old mothers in Group 
I and II, respectively, (Table 4).
Table 4: Comparison between Group I and II as regards birth order.
DS birth order Group INo. (%)
Group II
No. (%)
First 35 (35) 30 (30)
Second 31 (31) 30 (30)
Third 18 (18) 27 (27)
Fourth 12 (12) 8 (8)
Fifth 4 (4) 5 (5)
P value: 0.54.
Molecular analysis for C677T polymor-
phism was done to 20 young mothers of 
DS children; 35% of them had C677T 
mutation (10% had homozygous muta-
tion and 25% had heterozygous muta-
tion), (Fig. 1).
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When compared to Egyptian con-
trols7, our study showed higher risk 
(OR: 1.308) but with no significance 
difference (Table 5). Comparison of 
Fig. 1: Agarose gel showing: 1: Heterozygous MTHFR C677C/C677T genotype, 2: Homozygous MTH-
FR C677T/C677T genotype and 3: Wild alleles C677C/C677C genotype.
Table 5: MTHFR C677T mutation analysis in our study compared to Egyptian controls. 
C/C: Normal, C/T: Heterozygous, T/T: Homozygous mutation, CT/TT homozygous plus het-







C/T (10)2 (6.2)3 0.462 (0.2-10.8 1.6
T/T (25)5 (25)12 0.628 (0.3-3.3) 1
CT/TT (35)7 (31.2)15 0.420 (0.4-3.9) 1.3
Total (100)20 (100)48
our results to previous studies done 




Table 6: Comparison of our study and previous studies as regards MTHFR C667T mutation.
TT CT CC
Results of MTHFR C667T 
cases controls cases controls cases controls
James
et al.6
4 (8) 8 (14) 22 (44) 34 (59) 24 (48) 15 (26) Significant higher risk 
Coppede
et al. 
16 (20) 18 (16) 43 (54) 54 (48) 20 (25) 39 (35) Risk is not increased 
Scala 
et al.16
24 (25) 57 (22) 39 (41) 125 (48) 31 (32) 74 (28) Significant higher risk
Rai 
et al.15
12 (8) 2 (1) 40 (26) 39 (23) 97 (65) 124 (75) Significant higher risk in homozygous only
Our study 2 (10) - 5 (25) - 13 (65) - Non-significant higher risk
DISCUSSION                                                
Down syndrome (DS) or trisomy 21 
is a genetic disorder attributed to the 
presence and expression of three cop-
ies of genes located on chromosome 
21, which is mainly due to abnormal 
segregation during meiosis (maternal 
non-disjunction in 90% of cases)11. The 
mechanism underlying the meiotic non-
disjunction is poorly understood and is 
thought to have a multifactorial aetiol-
ogy, being influenced by both genetic 
and acquired factors6. One of these 
factors is abnormal folate metabolism 
theory in which a deficiency in dietary 
folate and methyle donor may result in 
DNA strand breaks and abnormal chro-
mosome segregation.12
In our work, MTHFR C677T polymor-
phism was found to be a possible mater-
nal genetic risk factor for DS in young 
mothers, although statistically insig-
nificant. This is consistent with Abdel 
meguid et al.7 study on Egyptian popu-
lation7 and confirms the meta-analysis 
done by Zintzaras, 2007 who concluded 
that the accumulated evidence indicated 
a lack of association between MTHFR 
C677T, MTHFR A1298C and MTRR 
A66G gene polymorphisms and ma-
ternal DS13. Actually, results of similar 
studies done on young mothers of DS 
were controversial, while James et al.6, 
Scala et al.14 and Rai et al.15 reported a 
significant increased  risk, Coppede et 
al. did not report a significance differ-
ence. 6,14-16 
It was suggested that this lack of asso-
ciation may be due to other gene poly-
morphisms involved in the homocyste-
ine and folate metabolic pathway that 
affect the risk of developing DS6,17. The 
risk effect may also depend on gene-
environment interaction between the 
genotype and dietary intake in particu-
lar folic acid consumption which could 
not be accurately studied in this work 
because none of the mothers had any 
vitamin supplement before or during 
pregnancy.18 
In this study, parental consanguinity was 
found in 22% of patients with DS with 
The first three studies were done on 
white population while the fourth was 
on Indians.
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insignificant difference between young 
and old mothers of DS. The percentage 
in the same range detected in the Egyp-
tian population (29-50%)19. It could be 
suggested that consanguinity has a little 
association with the incidence of DS 
and that the process of non-disjunction 
during oogenesis and spermatogenesis 
is rather a consequence of other causes 
particularly increased maternal age.20
Other possible risk factors studied in 
young mothers included increased pa-
ternal age (>49 years) which was found 
in only 3% of fathers in Group I com-
pared to 47% in Group II. This is con-
sistent with stoll et al.25 and cross and 
Hook10, studies and disagrees with few 
studies stating the strong association 
between advanced paternal age and 
increased risk of DS births3,10,21. In the 
latter, this risk was diminished with the 
appropriate adjustment for maternal age 
confirming the insignificant association.
On the other hand, maternal grand-
mothers’ age may have a significant 
effect only if the DS mother is above 
35 years. This is in contrast to the study 
done by Malini and Ramachandra, 2006 
who recorded that young age mothers 
(18 to 29 years) born to their mothers 
at the age 30 years and above produced 
as high as 91.3% of children with DS. 
The difference may be attributed to the 
small number of their study Group (69), 
compared to ours (200) and to the very 
high percentage of young mothers in 
Indian population (91.3%).22
The same finding was observed in the 
oral contraceptive use which had a sig-
nificant effect only if maternal age was 
above 35 years. This is in agreement of 
Lejeune and Prieur13, who found an ex-
cess of pill-taking by DS mothers over 
35 years23. This excess was significant 
when the delay between the cessation 
of pill-taking and the conception of the 
child is six months or less; when the 
duration of pill-taking has been longer 
than one year and when those two fac-
tors are present simultaneously. Other 
studies found no association but did not 
compare the use of oral contraceptive 
pills between different age Groups.24
Regarding birth order, most of DS were 
the first or second in order of birth with 
no significance difference between 
Groups I and II. This is consistent with 
Hay and Barbano, who suggested that 
the first-born infant is at higher risk 
independent on the maternal age and 
disagrees with Stoll et al. 1990, who re-
ported firstborns to be at lower risk of 
DS.5,25
CONCLUSION                                                
In conclusion, MTHFR C677T could 
not be considered as a maternal risk fac-
tor in young Egyptian mothers of DS. 
The risk effect may depend on gene-en-
vironment interaction between the gen-
otype and dietary intake in particular 
folic acid consumption which should be 
further studied on a larger scale popu-
lation including other MTHFR poly-
morphisms and environmental factors. 
Other risk factors may include the use 
of OCP in older mothers. Parents’ con-
sanguinity, paternal age and maternal 
grandparents’ ages were not found to be 
risk factors in DS in this study.
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